Simonen Piia, Stenman Ulf-Håkan, Gylling Helena
University of Helsinki and Helsinki University Central Hospital, Heart and Lung Center, Helsinki, P.O. BOX 700, 00029 HUS, Finland
University of Helsinki and Helsinki University Central Hospital, Clinical Chemistry, Helsinki, P.O. BOX 700, 00029 HUS, Finland.
Clin Sci (Lond). 2015 Sep;129(5):439-46. doi: 10.1042/CS20150193. Epub 2015 Apr 10.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates low-density lipoprotein (LDL) cholesterol (LDL-C) metabolism by targeting LDL receptors for degradation. Statins increase serum PCSK9 concentration limiting the potential of statins to reduce LDL-C, whereas ezetimibe, inhibitor of cholesterol absorption, has ambiguous effects on circulating PCSK9 levels. Plant stanols also reduce cholesterol absorption, but their effect on serum PCSK9 concentration is not known. Therefore, we performed a controlled, randomized, double-blind study, in which 92 normo- to moderately hypercholesterolaemic subjects (35 males and 57 females) consumed vegetable-oil spread 20 g/day enriched (plant stanol group, n=46) or not (control group, n=46) with plant stanols 3 g/day as ester for 6 months. Fasting blood samples were drawn at baseline and at the end of the study. Serum PCSK9 concentration was analysed with Quantikine Elisa Immunoassay, serum and lipoprotein lipids enzymatically and serum non-cholesterol sterols with GLC. At baseline, PCSK9 concentration varied from 91 to 716 ng/ml with a mean value of 278±11 (S.E.M.) ng/ml with no gender difference. It correlated with serum and LDL-C, serum triglycerides, age, body mass index (BMI) and plasma glucose concentration, but not with variables of cholesterol metabolism when adjusted to serum cholesterol. Plant stanols reduced LDL-C by 10% from controls (P<0.05), but PCSK9 levels were unchanged and did not differ between the groups. In conclusion, the present study demonstrated for the first time that inhibition of cholesterol absorption with plant stanol esters did not affect serum PCSK9 concentration. Thus, plant stanol esters provide an efficient dietary means to lower LDL-C without interfering with the PCSK9 metabolism and in this regard the LDL receptor-mediated cellular cholesterol uptake and removal.
前蛋白转化酶枯草溶菌素/kexin 9型(PCSK9)通过靶向低密度脂蛋白(LDL)受体进行降解来调节LDL胆固醇(LDL-C)代谢。他汀类药物会增加血清PCSK9浓度,限制了他汀类药物降低LDL-C的潜力,而胆固醇吸收抑制剂依折麦布对循环中的PCSK9水平影响不明确。植物甾烷醇也能降低胆固醇吸收,但其对血清PCSK9浓度的影响尚不清楚。因此,我们进行了一项对照、随机、双盲研究,92名正常至中度高胆固醇血症受试者(35名男性和57名女性)每天食用20克富含(植物甾烷醇组,n = 46)或不富含(对照组,n = 46)3克/天植物甾烷醇酯的植物油涂抹酱,持续6个月。在基线和研究结束时采集空腹血样。用Quantikine酶联免疫吸附测定法分析血清PCSK9浓度,用酶法分析血清和脂蛋白脂质,用气相色谱法分析血清非胆固醇甾醇。在基线时,PCSK9浓度在91至716纳克/毫升之间变化,平均值为278±11(标准误)纳克/毫升,无性别差异。它与血清和LDL-C、血清甘油三酯、年龄、体重指数(BMI)和血浆葡萄糖浓度相关,但在调整血清胆固醇后与胆固醇代谢变量无关。植物甾烷醇使LDL-C较对照组降低了10%(P<0.05),但PCSK9水平未改变,两组之间也无差异。总之,本研究首次证明,植物甾烷醇酯抑制胆固醇吸收不会影响血清PCSK9浓度。因此,植物甾烷醇酯提供了一种有效的饮食方法来降低LDL-C,而不会干扰PCSK9代谢以及LDL受体介导的细胞胆固醇摄取和清除。